Proteomics on NGS: Game-changing immunoassay technology to increase multiplexing and throughput
Protein biomarkers are increasingly used in clinical research to identify protein signatures that can predict outcomes, stratify patient populations, and provide insights into disease biology. Proteomics technologies have been restricted, however, by limitations in throughput, multiplexing level, specificity, and sensitivity.
Recent developments in multiplex technologies that enable high-throughput analysis of many proteins simultaneously, while using minimal volumes of biological samples, are accelerating the utility of proteomics.
Olink Proximity Extension Assay (PEA) technology featuring dual-recognition with matched DNA oligo-linked antibody pairs and qPCR readout has already been used to generate >160 million protein data points and ~400 peer-reviewed publications. Newly launched, Olink® Explore 1536 now takes this to an entirely new level, with PEA coupled to next-generation sequencing (NGS) readout enabling 1,472 proteins to be measured with just 3 µL plasma/serum and a throughput of 1.3 million protein data points/week on one instrument.
Join this webinar with Dr. Ida Grundberg, Chief Scientific Officer, and Dr. Erika Assarsson, Head of R&D, Olink Proteomics, to learn how this technology could be a game changer for proteomics.
Key learning objectives:
- What is Olink Explore 1536
- What are the benefits of PEA on NGS
Who should attend:
- Scientists with an interest in proteomic research who have access to samples
- Pharma/biotech, clinical and academic researchers
- Clinical research mass spec users running blood samples
- Research groups working with biobanks
- Researchers working with large scale epidemiology